ENLV vs. ORGS, ADAG, PYRGF, IMAB, INCR, DERM, CYTT, COYA, ORMP, and SGMT
Should you be buying Enlivex Therapeutics stock or one of its competitors? The main competitors of Enlivex Therapeutics include Orgenesis (ORGS), Adagene (ADAG), PyroGenesis Canada (PYRGF), I-Mab (IMAB), InterCure (INCR), Journey Medical (DERM), Cyteir Therapeutics (CYTT), Coya Therapeutics (COYA), Oramed Pharmaceuticals (ORMP), and Sagimet Biosciences (SGMT). These companies are all part of the "pharmaceutical preparations" industry.
Orgenesis (NASDAQ:ORGS) and Enlivex Therapeutics (NASDAQ:ENLV) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, media sentiment, community ranking, valuation, earnings, dividends, analyst recommendations and risk.
22.6% of Orgenesis shares are held by institutional investors. Comparatively, 1.0% of Enlivex Therapeutics shares are held by institutional investors. 5.7% of Orgenesis shares are held by insiders. Comparatively, 12.3% of Enlivex Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Enlivex Therapeutics has a consensus target price of $6.00, indicating a potential upside of 331.65%. Given Orgenesis' higher possible upside, analysts clearly believe Enlivex Therapeutics is more favorable than Orgenesis.
Enlivex Therapeutics has a net margin of 0.00% compared to Enlivex Therapeutics' net margin of -1,343.97%. Enlivex Therapeutics' return on equity of 0.00% beat Orgenesis' return on equity.
Enlivex Therapeutics received 49 more outperform votes than Orgenesis when rated by MarketBeat users. However, 100.00% of users gave Orgenesis an outperform vote while only 78.13% of users gave Enlivex Therapeutics an outperform vote.
Enlivex Therapeutics has lower revenue, but higher earnings than Orgenesis.
In the previous week, Enlivex Therapeutics had 1 more articles in the media than Orgenesis. MarketBeat recorded 2 mentions for Enlivex Therapeutics and 1 mentions for Orgenesis. Enlivex Therapeutics' average media sentiment score of 1.87 beat Orgenesis' score of 0.47 indicating that Orgenesis is being referred to more favorably in the media.
Orgenesis has a beta of 1.23, meaning that its share price is 23% more volatile than the S&P 500. Comparatively, Enlivex Therapeutics has a beta of 0.98, meaning that its share price is 2% less volatile than the S&P 500.
Summary
Enlivex Therapeutics beats Orgenesis on 8 of the 14 factors compared between the two stocks.
Get Enlivex Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ENLV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ENLV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Enlivex Therapeutics Competitors List
Related Companies and Tools
